Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01786382 · ClinicalTrials.gov registry record · Phase 1
A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole
A Phase 1 study, sponsored by Presidio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01786382 is a Phase 1 study that has completed, run by Presidio Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT01786382, a Phase 1 study, has completed, sponsored by Presidio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The primary objectives of the study are to: * Evaluate the potential effects of PPI-668 at steady state on the pharmacokinetic (PK) profile of midazolam following a single oral dose in human subjects. * Evaluate the potential effects of PPI-668 at steady state on the PK profile of omeprazole following a single oral dose in human subject
Interventions
- DRUG Midazolam
- DRUG Omeprazole
- DRUG Telaprevir
- DRUG PPI-668
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01786382
The ClinicalTrials.gov registry entry for NCT01786382 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Presidio Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Midazolam is the first listed.
NCT01786382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01786382 about?
NCT01786382 is a clinical study titled "A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole". The primary objectives of the study are to: * Evaluate the potential effects of PPI-668 at steady state on the pharmacokinetic (PK) profile of midazolam following a single oral dose in human subjects. * Evaluate the potential effects of PPI-668 at steady state on the PK profile of omeprazole follow...
What is the current status of trial NCT01786382?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-02. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01786382?
The interventions under investigation include: Midazolam (DRUG), Omeprazole (DRUG), Telaprevir (DRUG), PPI-668 (DRUG).
Who is sponsoring clinical trial NCT01786382?
This trial is sponsored by Presidio Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.